Clinical trials: Hematological Malignancies
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Hyperuricemia
Rasburicase (Fasturtec) Registration Trial
Primary: To compare the efficacy of Rasburicase versus allopurinol in controlling tumor lysis-related hyperuricemia in Chinese patients with leukemia or lymphoma.
- Trial name
- NCT00607152
- Testing
- Rasburicase, Allopurinol
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sanofi
Hematologic Diseases
Evaluation, Treatment, and Training for Patients With Blood Disorders
This study is designed to allow the evaluation, follow-up, and medical care of patients with blood disorders not currently participating in a research study being conducted by the Hematology Branch of the National Heart, Lung and…
- Trial name
- NCT00001397
- Where
- United States
- Volunteers
- 1,452 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Solid Tumor, Hematologic Malignancy
Implementation of an Oral Chemotherapy Adherence Intervention
The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural).
- Trial name
- NCT06989489
- Testing
- Multilevel Adherence Intervention
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens
- Conditions
- Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL), Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
- Trial name
- NCT01066468
- Testing
- Gleevec/Glivec
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
The study of whether an infusion of blood cells called lymphocytes from a donor can stimulate the immune system to fight your leukemia/lymphoma.
- Conditions
- Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma, T Cell Lymphomas
- Trial name
- 273 (NCT01685606)
- Testing
- cellular immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Brown University
Solid Tumor, Hematological Malignancies
The Good Patient Study
Adolescents with cancer weigh multiple influences in medical decision-making, including their own best interest, the perceived wishes of family members, and the interpreted preferences of the health care team.
- Conditions
- Solid Tumor, Hematological Malignancies, Brain Tumor
- Trial name
- NCT02199548
- Testing
- Interview
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- St. Jude Children's Research Hospital
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Malignant Hematologic Neoplasm
Fecal Microbiota Transplantation Among Adult Patients With Hematological Malignancies
In Hungary - in comparison to other member states of the European Union - about 75000 new cases of cancer are diagnosed annually, from which approximately 4500-5000 patients suffer from so-called malignant hematological diseases.
- Trial name
- HEMAT-FMT (NCT07172191)
- Testing
- Fecal Microbial Transplantation
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more…
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003960
- Testing
- busulfan, cyclophosphamide, methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematologic Malignancies, Hypoproliferative Thrombocytopenia
Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia
This is a prospective, multi-center, controlled, randomized, non-inferiority study to evaluate the clinical effectiveness of Conventional versus Mirasol-treated apheresis platelets in subjects with hypoproliferative…
- Trial name
- MIPLATE (NCT02964325)
- Testing
- Mirasol platelets (MIR PLTs), Reference platelets (REF PLTs)
- Where
- 10 sites in United States
- Volunteers
- 422 people
- Sponsor
- Terumo BCTbio
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hematologic Malignancy, Stem Cell Transplant
Mosaic Trial for Stem Cell Transplant Recipients
The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared…
- Conditions
- Hematologic Malignancy, Stem Cell Transplant, Bone Marrow Transplant, Leukemia
- Trial name
- Mosaic (NCT06960993)
- Testing
- Intervention website, Enhanced Usual Care (Control) Website
- Where
- 3 sites in United States
- Volunteers
- 356 people
- Sponsor
- Northwestern University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ROS1 translocation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439253
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Myeloid Hematological Malignancies
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
In this study, the investigators will use busulfan and cyclophosphamide (BuCy) backbone with the addition of fludarabine as the preparative Stem Cell Transplant (SCT) regimen.
- Trial name
- UCAML (NCT01247701)
- Testing
- Busulfan, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Baylor College of Medicine
Hematologic Neoplasms
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD).
- Trial name
- NCT04959175
- Testing
- Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Blood Cancer
The Leukemia and Lymphoma Society (LLS) National Research Registry
The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.
- Trial name
- NCT04806295
- Testing
- any/all treatments for blood cancer
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Blood Cancer United
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer.
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
- Trial name
- NCT07162181
- Testing
- Pirtobrutinib
- Where
- 6 sites in China
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Hematologic Malignancies
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
- Trial name
- NCT03320642
- Testing
- Itacitinib, Calcineurin inhibitor
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Nodal Lymphoma, Lymphoma With Cutaneous Involvement
Panobinostat Biological Correlates Study
This study is looking at the effects of Panobinostat, an investigational treatment, on cancer cells in patients who have Hodgkin lymphoma (a cancer of the immune system with specific Hodgkin/Reed Sternberg Cells), T-cell lymphoma…
- Conditions
- Nodal Lymphoma, Lymphoma With Cutaneous Involvement, Lymphoma in Leukemic Phase, Marrow Involvement With Lymphoma
- Trial name
- VEG VCA1 (NCT01658241)
- Testing
- panobinostat
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.